Evidence map›Paper›PMID 40376300›Full record

ArticlemicroLife2025

Disparate mechanisms counteract extraneous CRISPR RNA production in type II-C CRISPR-Cas systems.

Maximilian Feussner, Angela Migur, Alexander Mitrofanov, Omer S Alkhnbashi, Rolf Backofen, Chase L Beisel, Zasha Weinberg

Abstract read
In one paragraph

Article in microLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maximilian FeussnerBioinformatics Group, Department of Computer Science and Interdisciplinary Centre for Bioinformatics, Leipzig University, D-04107 Leipzig, Germany.
Angela MigurHelmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Centre for Infection Research (HZI), D-97080 Würzburg, Germany.
Alexander MitrofanovBioinformatics Group, Department of Computer Science, University of Freiburg, D-79110 Freiburg, Germany.
Omer S AlkhnbashiCenter for Applied and Translational Genomics (CATG), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Healthcare City, Dubai P.O. Box 505055, United Arab Emirates.
Rolf BackofenBioinformatics Group, Department of Computer Science, University of Freiburg, D-79110 Freiburg, Germany.
Chase L BeiselHelmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Centre for Infection Research (HZI), D-97080 Würzburg, Germany.
Zasha WeinbergBioinformatics Group, Department of Computer Science and Interdisciplinary Centre for Bioinformatics, Leipzig University, D-04107 Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas adaptive immune systems in bacteria and archaea enable precise targeting and elimination of invading genetic elements. An inherent feature of these systems is the 'extraneous' CRISPR RNA (ecrRNA), which is produced via the extra repeat in a CRISPR array lacking a corresponding spacer. As ecrRNAs would interact with the Cas machinery yet not direct acquired immunity, they pose a potential barrier to defence. Type II-A CRISPR-Cas systems resolve this barrier through the leader sequence upstream of a CRISPR array, which forms a hairpin structure with the extra repeat that inhibits ecrRNA production. However, the fate of ecrRNAs in other CRISPR types and subtypes remains to be explored. Here, we report that II-C systems likely employ disparate strategies to resolve the ecrRNA due to their distinct configuration in comparison to II-A. Applying bioinformatics analyses to over 650 II-C systems followed by experimental validation, we identified three strategies applicable to these systems: formation of an upstream Rho-independent terminator, formation of a hairpin that sequesters the ecrRNA guide, and mutations in the repeat expected to disrupt ecrRNA formation. These findings expand the list of mechanisms in CRISPR-Cas systems that could resolve the ecrRNA to optimize immune response.

Indexed as

CRISPR-CasCRISPR repeatsextraneous CRISPR RNAmutationsRNA secondary structuresType II-C CRISPR-Cas systems

Identifiers

PMID40376300
PMCPMC12080349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.